$CLNN + 101% today

$CLNN  a clinical-stage biopharma company, jump 101% today without any particular news.
We can perhaps attribute this to the bullish sentiment of Wall Street.

CLNN focuses on developing treatments for neurodegenerative diseases. The company’s leading pipeline product is CNM-Au8. There are few treatment options for these illnesses, and if CNM-Au8 proves safe and effective in clinical trials, it could become a major cash machine, but we have to be care because there is a long way to go with clinical test and lot can still go wrong for the company: regulatory roadblocks, negative results from late-stage clinical trials, etc.

Here is the link of the company website.

Here is the graph of today’s move.

Here is the 30 day overview.